EDUCATIONAL
Dr Sandy Adel
April 17, 2026 · 5 min read
If you work in cosmetic medicine, aesthetics, or wellness, the TGA’s April 2026 safety advisory is not background reading. It is a direct message to practitioners and clinic owners about where the regulator is focused right now, and what happens to those who get it wrong.
On 13 April 2026, the Therapeutic Goods Administration issued a safety advisory flagging a sharp rise in the import, supply, compounding, and advertising of unapproved peptide products across Australia. Products containing BPC-157, GHK-Cu, TB-500, retatrutide, and CJC-1295 are specifically named. None has been evaluated for safety, quality, or effectiveness. The TGA has confirmed it is actively monitoring this issue from both a safety and law enforcement perspective.
Peptides are short chains of amino acids that can mimic or stimulate biological processes, including those involved in metabolism, tissue repair, and growth. Some peptide-based medicines, insulin being the most familiar example, are approved by the TGA and listed on the Australian Register of Therapeutic Goods (ARTG).
The products named in the advisory are not those.
An unapproved peptide product is one that has not been assessed or included on the ARTG. Under the Therapeutic Goods Act 1989, all therapeutic goods supplied in Australia must be registered, listed, or supplied through a defined approved pathway. Products that sit outside this framework have no verified safety or quality profile in Australia, regardless of how they are marketed or labelled.
The TGA is responding to a growing gap between Australia’s legal framework and what is actually being promoted online.
Promotional content is appearing across social media platforms making health claims about unapproved peptides: weight loss, muscle growth, anti-ageing, enhanced cognitive and athletic performance. These claims are being made about products that have no regulatory basis for them in Australia.
The advisory specifically notes that many of these products are supplied in injectable form and are often labelled “research use only” or “not for human consumption.” That labelling does not change their legal status under Australian law.
The TGA’s safety advisory specifically names products containing BPC-157, GHK-Cu, TB-500, retatrutide, and CJC-1295. These are among the most widely promoted unapproved peptide products on Australian social media and wellness platforms, and they are commonly supplied in injectable form.
None of these products has been approved by the TGA for any indication in Australia.
The advisory identifies four areas: importing, compounding, supplying, and advertising.
Importing unapproved peptide products without appropriate authority is unlawful. The Personal Importation Scheme does not authorise the import of prescription-only medicines for supply or clinical use. The TGA has already issued infringement notices to practitioners who imported peptides without required approvals, with fines totalling over $43,000 across multiple enforcement actions. Australia’s peptide import rules make clear that authorisation requirements apply to all practitioners, not just commercial operators.
Compounding is equally regulated. The advisory specifically references the Pharmacy Board of Australia’s professional practice standards as applying to any pharmacist involved in compounding these products. Compounding an unapproved peptide outside a defined pathway is not a grey area.
Supply through a clinic or online interface is subject to the same framework. The TGA has previously found that online platforms allowing patients to self-select prescription medicines for subsequent prescribing and supply constitute advertising in themselves. Any clinic with a treatment menu or online booking flow that references peptide products should take note.
Advertising is where many clinics are most exposed. Prescription-only medicines cannot be advertised to the public under Australian law. Promoting a general class of products, including “peptides” broadly, can be treated as advertising prescription-only medicines. PeptideFinder Australia’s clinic advertising guidance outlines how this applies to public-facing content. If your clinic’s website, social posts, or patient emails mention unapproved peptides in connection with any health claim, that is a compliance issue
The risks are not theoretical. The advisory flags that reported adverse events associated with unapproved peptide products include severe allergic reactions, systemic inflammatory response syndrome, and generalised hypersensitivity symptoms including palpitations, intense full-body itching, pain, and sweating.
Most research on these substances remains preclinical: cell studies and animal models, with very limited human data. The World Anti-Doping Agency’s Prohibited List classifies BPC-157 under S0 Non-Approved Substances, noting it has no approval from any governmental regulatory health authority for human therapeutic use and no established safe dose.
Practitioners who supply or administer these products carry that uncertainty directly. There is no safety profile to refer to if something goes wrong.
No. This is one of the most common misconceptions in the peptide space, and the TGA advisory addresses it directly.
Labelling a product as a research compound does not change its classification as a therapeutic good under Australian law. It does not remove the obligations of anyone involved in its import, supply, compounding, or promotion. If you are stocking a product, recommending it to patients, or mentioning it on your website, the label on the vial is not a compliance defence.
The clinics managing this well are not waiting for an enforcement notice.
They are auditing their current product range and identifying anything not listed on the ARTG. They are reviewing all patient-facing content, including website copy, social posts, EDMs, and treatment menus, for any reference to unapproved products or health claims that cannot be substantiated under Australian advertising rules.
They are briefing their teams on what can and cannot be said to patients about peptide treatments. Australian Border Force routinely intercepts peptide shipments at the border, and staff who handle ordering, stock, or patient enquiries need to understand their position.
Where clinics have identified potential compliance issues, the advisory explicitly encourages reporting non-compliance to the TGA. Acting proactively places a clinic in a materially better position than responding to enforcement action after the fact.
If you are not certain, that uncertainty is worth resolving before the regulator resolves it for you. Non-compliant advertising does not have to be deliberate to attract regulatory action. In a space the TGA is now actively monitoring from a law enforcement perspective, staying in the grey carries real consequences.
ContentClicks works with cosmetic, dental, and aesthetic clinics across Australia to produce content that is visible, credible, and compliant. We understand the AHPRA and TGA frameworks, and we build that understanding into every piece of content we produce.
Get in touch with the ContentClicks team to talk about a compliance review of your current content.
Unapproved peptide products are therapeutic goods not listed on the Australian Register of Therapeutic Goods (ARTG). Under the Therapeutic Goods Act 1989, all therapeutic goods supplied in Australia must be registered, listed, or supplied through an approved pathway. Products not assessed by the TGA have no verified safety, quality, or efficacy profile, regardless of how they are labelled or what health claims are made about them online.
Not without appropriate regulatory approval. Both are unapproved therapeutic goods in Australia and have not been assessed by the TGA for safety or quality. Supplying, compounding, or advertising these products without authorisation may constitute a breach of the Therapeutic Goods Act 1989.
No. The scheme does not authorise the import of prescription-only medicines for supply or clinical use. The TGA advisory addresses this directly, and the regulator has issued infringement notices to practitioners who imported peptides without the required written authority.
It depends on what is being said. Prescription-only medicines cannot be advertised to the public under Australian law. Promoting peptides broadly, not just specific products, can be treated as advertising prescription-only medicines. Any clinic content that references unapproved peptides alongside health claims should be reviewed against the Therapeutic Goods Advertising Code before it is published.
Seek legal advice and review your obligations against the TGA advisory. The TGA explicitly encourages proactive reporting of non-compliance. Acting before an enforcement notice arrives gives you considerably more control over the outcome.
ContentClicks builds compliance-first content marketing for healthcare and medical aesthetics practices. Let’s talk.
Plastic surgeons, cosmetic dentists, and aesthetic clinics trust us to get them found. AI-driven content and marketing, built for the way people search today.
